297 related articles for article (PubMed ID: 20228226)
1. Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy.
Asano Y; Stawski L; Hant F; Highland K; Silver R; Szalai G; Watson DK; Trojanowska M
Am J Pathol; 2010 Apr; 176(4):1983-98. PubMed ID: 20228226
[TBL] [Abstract][Full Text] [Related]
2. Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis.
Taniguchi T; Asano Y; Nakamura K; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Sato S
J Rheumatol; 2017 Aug; 44(8):1198-1205. PubMed ID: 28507181
[TBL] [Abstract][Full Text] [Related]
3. A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and vasculopathy in systemic sclerosis.
Yamashita T; Asano Y; Taniguchi T; Nakamura K; Saigusa R; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
Exp Dermatol; 2016 Apr; 25(4):287-92. PubMed ID: 26661692
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor blockade ameliorates vascular fragility in endothelial cell-specific Fli-1-knockout mice by increasing Fli-1 DNA binding ability.
Akamata K; Asano Y; Yamashita T; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Trojanowska M; Sato S
Arthritis Rheumatol; 2015 May; 67(5):1335-44. PubMed ID: 25707716
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic suppression of Fli1, a potential predisposing factor in the pathogenesis of systemic sclerosis.
Asano Y
Int J Biochem Cell Biol; 2015 Oct; 67():86-91. PubMed ID: 26055516
[TBL] [Abstract][Full Text] [Related]
6. Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in prothrombotic conditions.
Saigusa R; Asano Y; Yamashita T; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
Br J Dermatol; 2016 Feb; 174(2):338-47. PubMed ID: 26399195
[TBL] [Abstract][Full Text] [Related]
7. A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.
Taniguchi T; Miyagawa T; Tamaki Z; Nakamura K; Yamashita T; Saigusa R; Takahashi T; Toyama T; Ichimura Y; Yoshizaki A; Tada Y; Sugaya M; Kadono T; Sato S; Asano Y
Arch Dermatol Res; 2017 Dec; 309(10):833-842. PubMed ID: 29038846
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis.
Yamashita T; Asano Y; Saigusa R; Taniguchi T; Nakamura K; Miura S; Toyama T; Takahashi T; Ichimura Y; Hirabayashi M; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
J Dermatol Sci; 2019 Jan; 93(1):24-32. PubMed ID: 30270117
[TBL] [Abstract][Full Text] [Related]
10. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
Asano Y
Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
[TBL] [Abstract][Full Text] [Related]
11. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts.
Wang Y; Fan PS; Kahaleh B
Arthritis Rheum; 2006 Jul; 54(7):2271-9. PubMed ID: 16802366
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy.
Yamashita T; Asano Y; Saigusa R; Taniguchi T; Hirabayashi M; Miyagawa T; Nakamura K; Miura S; Yoshizaki A; Trojanowska M; Sato S
J Invest Dermatol; 2019 May; 139(5):1150-1160. PubMed ID: 30508546
[TBL] [Abstract][Full Text] [Related]
13. Altered Properties of Endothelial Cells and Mesenchymal Stem Cells Underlying the Development of Scleroderma-like Vasculopathy in KLF5
Nakamura K; Taniguchi T; Hirabayashi M; Yamashita T; Saigusa R; Miura S; Takahashi T; Toyama T; Ichimura Y; Yoshizaki A; Trojanowska M; Fujiu K; Nagai R; Sato S; Asano Y
Arthritis Rheumatol; 2020 Dec; 72(12):2136-2146. PubMed ID: 32627966
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in animal models of systemic sclerosis.
Asano Y
J Dermatol; 2016 Jan; 43(1):19-28. PubMed ID: 26782003
[TBL] [Abstract][Full Text] [Related]
15. A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis.
Saigusa R; Asano Y; Taniguchi T; Yamashita T; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Exp Dermatol; 2015 Feb; 24(2):127-32. PubMed ID: 25421497
[TBL] [Abstract][Full Text] [Related]
16. Fli1 Downregulation in Scleroderma Myeloid Cells Has Profibrotic and Proinflammatory Effects.
Bujor AM; El Adili F; Parvez A; Marden G; Trojanowska M
Front Immunol; 2020; 11():800. PubMed ID: 32508810
[TBL] [Abstract][Full Text] [Related]
17. A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis.
Noda S; Asano Y; Akamata K; Aozasa N; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
PLoS One; 2012; 7(2):e32272. PubMed ID: 22384200
[TBL] [Abstract][Full Text] [Related]
18. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1.
Akamata K; Asano Y; Aozasa N; Noda S; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sato S
Arthritis Res Ther; 2014 Apr; 16(2):R86. PubMed ID: 24708674
[TBL] [Abstract][Full Text] [Related]
19. Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis.
Ikawa T; Miyagawa T; Fukui Y; Toyama S; Omatsu J; Awaji K; Norimatsu Y; Watanabe Y; Yoshizaki A; Sato S; Asano Y
Arthritis Res Ther; 2021 Nov; 23(1):283. PubMed ID: 34774095
[TBL] [Abstract][Full Text] [Related]
20. A possible contribution of lipocalin-2 to the development of dermal fibrosis, pulmonary vascular involvement and renal dysfunction in systemic sclerosis.
Takahashi T; Asano Y; Noda S; Aozasa N; Akamata K; Taniguchi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2015 Sep; 173(3):681-9. PubMed ID: 25781362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
